Page 1568 - Williams Hematology ( PDFDrive )

1542 Part XI: Malignant Lymphoid Diseases Chapter 92: Chronic Lymphocytic Leukemia 1543

men and increases in incidence with age. The cumulative annual risk of immature B cells with distinct molecular features and outcomes (Chap.
patients with MBL who require CLL-specific therapy is approximately 91). Transformation of CLL into ALL has been reported and managed
1 percent. 16,17,420 Retrospective analysis of samples collected on longi- with regimens suitable for ALL. 437–439
tudinal, prospective studies have also demonstrated that the develop-
ment of overt CLL is almost always preceded by MBL. Management
423
of patients with MBL is similar to patients with early stage CLL and REFERENCES
the vast majority of these patients can be followed with watchful wait- 1. Hallek M, Cheson BD, Catovsky D, et al: Guidelines for the diagnosis and treatment of
ing. Like early stage CLL, these patients are predisposed to a higher fre- chronic lymphocytic leukemia: A report from the International Workshop on Chronic
quency of infections and also secondary malignancies mandating follow Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996
up similar to that recommended for CLL. Our own practice is to see guidelines. Blood 111:5446–5456, 2008.
MBL patients yearly with exams and complete blood count assessment. 2. Cartwright RA, Gurney KA, Moorman AV: Sex ratios and the risks of haematological
malignancies. Br J Haematol 118:1071–1077, 2002.
3. Diehl LF, Karnell LH, Menck HR: The American College of Surgeons Commission on
Cancer and the American Cancer Society. The National Cancer Data Base report on
SMALL LYMPHOCYTIC LYMPHOMA age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia.
Cancer 86:2684–2692, 1999.
4. Adami HO, Tsaih S, Lambe M, et al: Pregnancy and risk of non-Hodgkin’s lymphoma:
Small lymphocytic B-cell lymphoma (SLL) is closely related to CLL A prospective study. Int J Cancer 70:155–158, 1997.
and mimics it with regards to clinical course and outcomes. The malig- 5. Ahn YO, Koo HH, Park BJ, et al: Incidence estimation of leukemia among Koreans.
nant B cells have similar immunophenotypic features and prognostic J Korean Med Sci 6:299–307, 1991.
markers on lymph node assessment but without the presence of malig- 6. Haenszel W, Kurihara M: Studies of Japanese migrants. I. Mortality from cancer and
other diseases among Japanese in the United States. J Natl Cancer Inst 40:43–68, 1968.
nant monoclonal B-cell lymphocytosis on blood or marrow assess- 7. Goldin LR, Bjorkholm M, Kristinsson SY, et al: Elevated risk of chronic lymphocytic
ment. Treatment and outcomes of these patients are similar to those leukemia and other indolent non-Hodgkin’s lymphomas among relatives of patients
for patients with CLL and as such this disorder should be considered with chronic lymphocytic leukemia. Haematologica 94:647–653, 2009.
analogous to CLL. 1,45,424,425 8. Wang SS, Slager SL, Brennan P, et al: Family history of hematopoietic malignancies and
risk of non-Hodgkin lymphoma (NHL): A pooled analysis of 10,211 cases and 11,905
controls from the International Lymphoma Epidemiology Consortium (InterLymph).
Blood 109:3479–3488, 2007.
DIFFERENTIAL DIAGNOSES 9. Slager SL, Benavente Y, Blair A, et al: Medical history, lifestyle, family history, and occu-
pational risk factors for chronic lymphocytic leukemia/small lymphocytic lymphoma:
Multiple low-grade lymphoid malignancies can mimic the presentation The InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr
2014:41–51, 2014.
and laboratory evidence of CLL and are discussed in detail in the chap- 10. Marwick C: Link found between Agent Orange and chronic lymphocytic leukaemia.
ters on non-Hodgkin lymphomas (Chaps. 95, 96, 99–101). The most BMJ 326:242, 2003.
common entities mimicking CLL are briefly discussed below. 11. Floderus B, Persson T, Stenlund C, et al: Occupational exposure to electromagnetic
fields in relation to leukemia and brain tumors: A case-control study in Sweden. Cancer
Causes Control 4:465–476, 1993.
MANTLE CELL LYMPHOMA 12. Feychting M, Forssen U, Floderus B: Occupational and residential magnetic field expo-
sure and leukemia and central nervous system tumors. Epidemiology 8:384–389, 1997.
Mantle cell lymphoma frequently mimics the clinical presentation and 13. Vrijheid M, Cardis E, Ashmore P, et al: Ionizing radiation and risk of chronic lym-
laboratory findings observed in patients with CLL (Chap. 100). How- phocytic leukemia in the 15-country study of nuclear industry workers. Radiat Res
170:661–665, 2008.
ever, the malignant lymphocytes observed in mantle cell lymphoma 14. Richardson DB, Wing S, Schroeder J, et al: Ionizing radiation and chronic lymphocytic
express CD5 without coexpression of CD23 and have a higher level of leukemia. Environ Health Perspect 113:1–5, 2005.
expression of CD79. Cases of CD23-negative CLL and CD23-positive 15. Abramenko I, Bilous N, Chumak A, et al: Chronic lymphocytic leukemia patients
mantle cell lymphoma have been described. An important discriminat- exposed to ionizing radiation due to the Chernobyl NPP accident—With focus on
immunoglobulin heavy chain gene analysis. Leuk Res 32:535–545, 2008.
ing feature between the two disorders is the presence of t(11;14) in man- 16. Rawstron AC, Yuille MR, Fuller J, et al: Inherited predisposition to CLL is detectable as
tle cell lymphoma, which results in the bcl-1-IGH translocation and the subclinical monoclonal B-lymphocyte expansion. Blood 100:2289–2290, 2002.
overexpression of cyclin D1. Therapy for mantle cell lymphoma employs 17. Rawstron AC, Bennett FL, O’Connor SJ, et al: Monoclonal B-cell lymphocytosis and
chronic lymphocytic leukemia. N Engl J Med 359:575–583, 2008.
some of the agents used for CLL but is covered in detail elsewhere. 426–429 18. Kristinsson SY, Bjorkholm M, Goldin LR, et al: Risk of lymphoproliferative disorders
among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macro-
globulinemia patients: A population-based study in Sweden. Blood 112:3052–3056,
HAIRY CELL LEUKEMIA 2008.
19. Raval A, Tanner SM, Byrd JC, et al: Downregulation of death-associated protein kinase
Hairy cell leukemia (HCL) presents with B symptoms, splenomegaly and 1 (DAPK1) in chronic lymphocytic leukemia. Cell 129:879–890, 2007.
the presence of typical villous “hairy” projections from the surface of its 20. Perez-Chacon G, Contreras-Martin B, Cuni S, et al: Polymorphism in the CD5 gene
cells (Chap. 93). The cells are also strongly positive for tartrate-resistant promoter in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Am J Clin
acid phosphatase (TRAP) and express CD11c, CD25, and CD103. With Pathol 123:646–650, 2005.
the discovery of the BRAF V600E in HCL, significant improvements have 21. Aydin S, Rossi D, Bergui L, et al: CD38 gene polymorphism and chronic lymphocytic
leukemia: A role in transformation to Richter syndrome? Blood 111:5646–5653, 2008.
been made in the availability of therapeutic agents for the management 22. Jevtovic-Stoimenov T, Kocic G, Pavlovic D, et al: Polymorphisms of tumor-necrosis
of these patients. 430–433 factor-alpha -308 and lymphotoxin-alpha + 250: Possible modulation of susceptibility
to apoptosis in chronic lymphocytic leukemia and non-Hodgkin lymphoma mononu-
clear cells. Leuk Lymphoma 49:2163–2169, 2008.
OTHER LYMPHOID MALIGNANCIES 23. Sellick GS, Goldin LR, Wild RW, et al: A high-density SNP genome-wide linkage search
of 206 families identifies susceptibility loci for chronic lymphocytic leukemia. Blood
Various low-grade lymphoid malignancies can mimic the clinical and 110:3326–3333, 2007.
laboratory presentation of CLL and include marginal zone lymphomas 24. Di Bernardo MC, Crowther-Swanepoel D, Broderick P, et al: A genome-wide associa-
and lymphoplasmacytic lymphomas. However, pathologic evaluation tion study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet
40:1204–1210, 2008.
results in the identification of surface markers CD19 and CD20 without 25. Marti GE, Faguet G, Bertin P, et al: CD20 and CD5 expression in B-chronic lympho-
coexpression of CD5 or CD23. Therapy is directed at the specific lym- cytic leukemia. Ann N Y Acad Sci 651:480–483, 1992.
phoid malignancy identified. 434–436 B-cell ALL is also included in the list 26. Almasri NM, Duque RE, Iturraspe J, et al: Reduced expression of CD20 antigen as a
characteristic marker for chronic lymphocytic leukemia. Am J Hematol 40:259–263,
of differential diagnoses, but it is an aggressive malignancy involving 1992.

Kaushansky_chapter 92_p1527-1552.indd 1543 9/18/15 10:49 AM